Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
30 Results for "
elastase release
" in MedChemExpress (MCE) Product Catalog:
Products (30)
30 Results for "elastase release" in MCE Product Catalog:
11
11 Publications Verification
Synonyms: AZD9668
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Alvelestat (AZD9668) is an orally active, selective inhibitor of neutrophil elastase. Alvelestat reduces elastase activity, myeloperoxidase release, neutrophil recruitment and activation, and calcium phosphate precipitation; promotes smooth muscle cell colonization and collagen deposition; and inhibits the formation of neutrophil extracellular traps (NETs) as well as NET-derived neutrophil elastase activity. Alvelestat restores endothelial dysfunction, regulates antioxidant factors, improves the expression of endothelial tight junctions, reduces vascular leakage, and accelerates wound healing. Alvelestat prevents pulmonary hemorrhage, matrix protein degradation, airspace enlargement, and small airway wall remodeling; and alleviates cigarette-induced inflammatory responses. Alvelestat inhibits the growth of abdominal aortic aneurysms exacerbated by Porphyromonas gingivalis. Alvelestat can be used in research related to chronic obstructive pulmonary disease, abdominal aortic aneurysm, radiation-induced skin injury, and bronchiectasis .
5
5 Cited Publications
Research Areas:
HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .
4
Category:
Flavonoids Neurological Disease Flavones Rutaceae Plants Disease Research Fields Citrus Cancer
Target:
Target:
Research Areas:
Neutrophil elastase inhibitor 5 is an inhibitor of human neutrophil elastase (HNE), proteinase 3 (PR3) and sirt2, with IC50 values of 4.91, 20.69 and 2.42 μM, respectively. Neutrophil elastase inhibitor 5 inhibits superoxide anion production and elastase release in human neutrophils. Neutrophil elastase inhibitor 5 can be used for the research of neutrophil inflammatory diseases .
Cat. No.: HY-N13250
Cat. No.: HY-132132
CAS No.: 1234707-32-4
Target:
Research Areas:
Neutrophil elastase inhibitor 3 (compound 13), a benzoxazinone analog, shows effects on superoxide anion generation and exhibits as a neutrophil elastase (NE) inhibitor, with an IC50 of 80.8 nM for NE release .
Cat. No.: HY-N10450
CAS No.: 72755-19-2
Synonyms: 1-Ethoxycarbonyl-β-carboline
Target:
Cat. No.: HY-164429
CAS No.: 2418533-90-9
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .
Cat. No.: HY-P4126
CAS No.: 113277-37-5
Cat. No.: HY-15651A
CAS No.: 1240425-05-1
Synonyms: AZD9668 tosylate
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Alvelestat tosylate (AZD9668 tosylate) is an orally active, selective inhibitor of neutrophil elastase. Alvelestat tosylate reduces elastase activity, myeloperoxidase release, neutrophil recruitment and activation, and calcium phosphate precipitation; promotes smooth muscle cell colonization and collagen deposition; and inhibits the formation of neutrophil extracellular traps (NETs) as well as NET-derived neutrophil elastase activity. Alvelestat tosylate restores endothelial dysfunction, regulates antioxidant factors, improves the expression of endothelial tight junctions, reduces vascular leakage, and accelerates wound healing. Alvelestat tosylate prevents pulmonary hemorrhage, matrix protein degradation, airspace enlargement, and small airway wall remodeling; and alleviates cigarette-induced inflammatory responses. Alvelestat tosylate inhibits the growth of abdominal aortic aneurysms exacerbated by Porphyromonas gingivalis. Alvelestat tosylate can be used in research related to chronic obstructive pulmonary disease, abdominal aortic aneurysm, radiation-induced skin injury, and bronchiectasis .
Cat. No.: HY-15651R
CAS No.: 848141-11-7
Synonyms: AZD9668 (Standard)
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Alvelestat (Standard) (AZD9668 (Standard)) is the analytical standard of Alvelestat (HY-15651). This product is intended for research and analytical applications. Alvelestat (AZD9668) is an orally active, selective inhibitor of neutrophil elastase. Alvelestat reduces elastase activity, myeloperoxidase release, neutrophil recruitment and activation, and calcium phosphate precipitation; promotes smooth muscle cell colonization and collagen deposition; and inhibits the formation of neutrophil extracellular traps (NETs) as well as NET-derived neutrophil elastase activity. Alvelestat restores endothelial dysfunction, regulates antioxidant factors, improves the expression of endothelial tight junctions, reduces vascular leakage, and accelerates wound healing. Alvelestat prevents pulmonary hemorrhage, matrix protein degradation, airspace enlargement, and small airway wall remodeling; and alleviates cigarette-induced inflammatory responses. Alvelestat inhibits the growth of abdominal aortic aneurysms exacerbated by Porphyromonas gingivalis. Alvelestat can be used in research related to chronic obstructive pulmonary disease, abdominal aortic aneurysm, radiation-induced skin injury, and bronchiectasis .
Cat. No.: HY-N3566
CAS No.: 55610-01-0
Target:
Cat. No.: HY-169324
CAS No.: 2921735-91-1
Synonyms: Mal-Exo-EEVC-Exatecan
Target:
Research Areas:
APL-1092 is an EEVC linker-payload conjugate composed of exatecan, a stabilizer that prevents premature payload release, and a cleavage substrate for cathepsin B . APL-1092 resists premature payload release mediated by human neutrophil elastase and carboxylesterase, maintains payload stability in mouse plasma, and retains cathepsin B-mediated cleavage activity in target cells . APL-1092 exhibits dose-dependent tumor growth inhibition in xenograft mice . APL-1092 can be used in gastric cancer-related research .
Cat. No.: HY-106899
CAS No.: 135947-75-0
Research Areas:
MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
Cat. No.: HY-N11564
CAS No.: 97399-89-8
Target:
Cat. No.: HY-N8447
CAS No.: 1891097-17-8
Target:
Cat. No.: HY-176403
CAS No.: 3058943-53-3
Target:
Research Areas:
FPR1 antagonist 3 (compound 10) is a potent and selective FPR1 antagonist. FPR1 antagonist 3 inhibits superoxide anion generation and elastase release with IC50s of 0.33 and 0.84 μM, respectively .
Cat. No.: HY-15651S
Synonyms: AZD9668-13C,d3
Category:
Cat. No.: HY-106899A
CAS No.: 143445-03-8
Synonyms: (rel)-L-680573
Research Areas:
(rel)-MK 287 ((rel)-L-680573) is a relative configuration of MK 287. MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
